Womens Health
Mfg : StrivePT141 Mini Troche
Prescription Libido Therapy – Sublingual Troche Bremelanotide (PT-141) Mini Troche is a prescription medication that enhances sexual desire and arousal by acting on the central nervous system.
Neuroscience-Based Action Activates melanocortin receptors in the brain to support natural sexual desire and arousal
Works for Both Men and Women Effective for both genders, addressing libido and arousal concerns
Convenient Sublingual Format Mini troche dissolves under the tongue for rapid absorption within 30-60 minutes
Prescription Required Available only through licensed healthcare providers FDA-approved for HSDD in premenopausal women
Maximum Doses: 4
Per Dose $ 00.00
Total Price
Bremelanotide (PT-141) Mini Troche is a prescription compounded medication that enhances sexual desire and arousal by acting on the central nervous system. It is a melanocortin receptor agonist that works by activating pathways in the brain involved in sexual responses, rather than acting on blood vessels like traditional ED medications. The information provided is for educational purposes only and does not replace professional medical advice.
Product Name: Bremelanotide Mini Troche
Category: Prescription Sexual Wellness
Active Ingredient: Bremelanotide (PT-141)
Strength: 1 mg per troche
Form: Sublingual Troche (Mini Dissolvable Tablet)
Administration: Dissolve under the tongue 30-60 minutes before sexual activity
Indication: Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women off-label use for men
Availability: Prescription only
Bremelanotide, known commercially as Vyleesi®, is a synthetic peptide that activates melanocortin receptors involved in regulating sexual desire and neuroendocrine signaling. The drug was developed after researchers discovered its sexual arousal effects during testing of a related compound, Melanotan II. It received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Bremelanotide is a melanocortin receptor agonist that acts on MC3 and MC4 receptors in the central nervous system. Unlike traditional erectile dysfunction medications that work on blood vessels, Bremelanotide targets the brains natural pathways to create sexual desire and arousal.
Key Mechanisms:
Central Nervous System Action: Activates melanocortin receptors in the brain involved in sexual responses.
Non-Sex Specific: Works in both men and women, as the mechanism of action is not sex-specific.
Distinct from ED Medications: Unlike Viagra or Cialis, which work on blood vessels, PT-141 targets the neurological pathways of sexual desire.
Enhances Sexual Desire: Activates neural pathways linked to sexual arousal and desire.
Rapid Onset: Effects typically begin within 30-60 minutes of administration.
Long Duration: Effects can last 6-8 hours.
Works for Both Men and Women: Effective for both genders, addressing desire and arousal.
Convenient Troche Format: Sublingual administration provides rapid absorption without injections.
Premenopausal women with diagnosed hypoactive sexual desire disorder (HSDD)
Men seeking to address low libido or erectile function concerns (off-label use)
Individuals with stress or age-related desire changes
Those seeking an alternative to traditional ED medications
Couples looking to enhance intimacy and connection
Place one mini troche under the tongue and allow it to dissolve completely (approximately 10-15 minutes). Take 30-60 minutes before anticipated sexual activity. Do not exceed the prescribed dosage or use more than once daily unless directed by your healthcare provider. Avoid eating or drinking for 30 minutes after taking the troche.
FDA Approval: Bremelanotide (Vyleesi®) is FDA-approved for the treatment of HSDD in premenopausal women. All other uses, including in men, are considered off-label and must be discussed with a licensed medical provider.
Contraindications: Do not use if you have known hypersensitivity to bremelanotide, uncontrolled hypertension, or significant cardiovascular disease. Not recommended during pregnancy.
Common Side Effects: May include nausea, flushing, headache, dizziness, and injection site reactions (for injectable forms). Nausea is the most common side effect, reported in approximately 40% of users in clinical trials.
Serious Side Effects: Monitor for increased blood pressure. Use with caution in patients with cardiovascular disease, renal or hepatic impairment.
Drug Interactions: Inform your healthcare provider of all medications and supplements you are taking. Do not use with alcohol or recreational drugs during treatment.
Bremelanotide Mini Troches are prepared by licensed compounding pharmacies that adhere to strict USP guidelines and regulatory standards. All ingredients are sourced from FDA-registered suppliers to ensure pharmaceutical-grade purity, potency, and consistency.
